Clinical Trial Highlights

Recently acquired medicines IPSEN Innovation for patient care Г Г Bylvay (odevixibat) €23m TAZVERIK (tazemetostat) tablets 200 mg €19m Growth of 140%1 Strong momentum in North America and Europe Increasing number of treated PFIC patients Growth of 18% in commercial sales² Focus on all-comers, new-patient starts & duration of therapy Increasing share of office-based patients All growth rates are at constant exchange rates. 1. Reference to Albireo's published H1 2022 performance. 2.. Reference to Epizyme's published H1 2022 performance. PFIC: progressive familial intrahepatic cholestasis. 7

View entire presentation